FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAHDUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
